BMW Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 10:30 am

Competitors of BMW Industries Ltd

All Competitor Stocks of BMW Industries Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:00 am

Below is a detailed analysis of the quarterly data for BMW Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 149.00 Cr.. The value appears to be declining and may need further review. It has decreased from 157.00 Cr. (Mar 2025) to 149.00 Cr., marking a decrease of 8.00 Cr..
• For Expenses, as of Jun 2025, the value is 117.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.00 Cr. (Mar 2025) to 117.00 Cr., marking a decrease of 7.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
• For OPM %, as of Jun 2025, the value is 21.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00%.
• For Other Income, as of Jun 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 3.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 25.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 3.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.68. The value appears to be declining and may need further review. It has decreased from 0.78 (Mar 2025) to 0.68, marking a decrease of 0.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 3:44 am

Growth

Last Updated: September 5, 2025, 2:46 pm

Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for BMW Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 5. It has increased from 2.83 (Mar 24) to 3.33, marking an increase of 0.50.
• For Diluted EPS (Rs.), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 5. It has increased from 2.83 (Mar 24) to 3.33, marking an increase of 0.50.
• For Cash EPS (Rs.), as of Mar 25, the value is 5.28. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 5.28, marking an increase of 0.47.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 32.50. It has increased from 29.38 (Mar 24) to 32.50, marking an increase of 3.12.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 32.50. It has increased from 29.38 (Mar 24) to 32.50, marking an increase of 3.12.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 27.93. It has increased from 26.58 (Mar 24) to 27.93, marking an increase of 1.35.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 6.98. This value is within the healthy range. It has increased from 6.69 (Mar 24) to 6.98, marking an increase of 0.29.
• For PBIT / Share (Rs.), as of Mar 25, the value is 5.02. This value is within the healthy range. It has increased from 4.71 (Mar 24) to 5.02, marking an increase of 0.31.
• For PBT / Share (Rs.), as of Mar 25, the value is 4.43. This value is within the healthy range. It has increased from 3.83 (Mar 24) to 4.43, marking an increase of 0.60.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 3.33, marking an increase of 0.50.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 3.33, marking an increase of 0.50.
• For PBDIT Margin (%), as of Mar 25, the value is 24.99. This value is within the healthy range. It has decreased from 25.17 (Mar 24) to 24.99, marking a decrease of 0.18.
• For PBIT Margin (%), as of Mar 25, the value is 17.98. This value is within the healthy range. It has increased from 17.73 (Mar 24) to 17.98, marking an increase of 0.25.
• For PBT Margin (%), as of Mar 25, the value is 15.87. This value is within the healthy range. It has increased from 14.42 (Mar 24) to 15.87, marking an increase of 1.45.
• For Net Profit Margin (%), as of Mar 25, the value is 11.90. This value exceeds the healthy maximum of 10. It has increased from 10.66 (Mar 24) to 11.90, marking an increase of 1.24.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.93. This value is within the healthy range. It has increased from 10.65 (Mar 24) to 11.93, marking an increase of 1.28.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.25. This value is below the healthy minimum of 15. It has increased from 9.64 (Mar 24) to 10.25, marking an increase of 0.61.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.63. This value is within the healthy range. It has decreased from 13.56 (Mar 24) to 12.63, marking a decrease of 0.93.
• For Return On Assets (%), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 7.24 (Mar 24) to 7.39, marking an increase of 0.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.06 (Mar 24) to 0.10, marking an increase of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.19, marking an increase of 0.07.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has increased from 0.64 (Mar 24) to 0.66, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has increased from 2.08 (Mar 24) to 2.27, marking an increase of 0.19.
• For Quick Ratio (X), as of Mar 25, the value is 1.80. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 1.80, marking an increase of 0.42.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.95. This value exceeds the healthy maximum of 8. It has increased from 1.81 (Mar 24) to 9.95, marking an increase of 8.14.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.29. This value is below the healthy minimum of 20. It has decreased from 7.76 (Mar 24) to 6.29, marking a decrease of 1.47.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.96. This value is below the healthy minimum of 20. It has decreased from 4.57 (Mar 24) to 3.96, marking a decrease of 0.61.
• For Earning Retention Ratio (%), as of Mar 25, the value is 93.71. This value exceeds the healthy maximum of 70. It has increased from 92.24 (Mar 24) to 93.71, marking an increase of 1.47.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.04. This value exceeds the healthy maximum of 70. It has increased from 95.43 (Mar 24) to 96.04, marking an increase of 0.61.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 11.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 11.85, marking an increase of 4.24.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.64. This value is within the healthy range. It has increased from 4.22 (Mar 24) to 6.64, marking an increase of 2.42.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,195.10. It has decreased from 1,323.06 (Mar 24) to 1,195.10, marking a decrease of 127.96.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.90, marking a decrease of 0.31.
• For EV / EBITDA (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has decreased from 8.78 (Mar 24) to 7.60, marking a decrease of 1.18.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.69, marking a decrease of 0.39.
• For Retention Ratios (%), as of Mar 25, the value is 93.70. This value exceeds the healthy maximum of 70. It has increased from 92.23 (Mar 24) to 93.70, marking an increase of 1.47.
• For Price / BV (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has decreased from 1.88 (Mar 24) to 1.45, marking a decrease of 0.43.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.69, marking a decrease of 0.39.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.07, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness